comprehensive chromosome screening 为基础的胚胎植入前非整倍体遗传学检测在体外受精患者中的效果:系统综述与Meta分析
该系统综述与Meta分析检索了Medline、EMBASE、Cochrane对照试验中心注册库和ClinicalTrials.gov截至2022年2月28日的随机对照试验,纳入9项试验共3334名接受体外受精的女性。总体而言,胚胎植入前非整倍体遗传学检测(PGT-A)未增加活产率(RR 1.13,95%CI 0.96-1.34,I²=79%);但在高龄产妇中PGT-A提高了活产率(RR 1.34,95%CI 1.02-1.77,I²=50%),在非高龄产妇中未提高(RR 0.94,95%CI 0.89-0.99,I²=0%)。结论认为PGT-A可提高高龄产妇的活产率。
要点
- 总体PGT-A未增加活产率(RR 1.13,95%CI 0.96-1.34)。
- 高龄产妇中PGT-A提高活产率(RR 1.34,95%CI 1.02-1.77)。
- 非高龄产妇中PGT-A未提高活产率(RR 0.94,95%CI 0.89-0.99)。
核心结论
- 胚胎植入前非整倍体遗传学检测(PGT-A)可提高高龄产妇的活产率。
研究设计与样本
- 系统综述与Meta分析,检索Medline、EMBASE、Cochrane对照试验中心注册库和ClinicalTrials.gov从建库至2022年2月28日,无语言限制,纳入9项随机对照试验共3334名接受体外受精的女性。
主要发现
- 总体PGT-A与活产率增加无关(RR 1.13,95%CI 0.96-1.34,I²=79%)。
- 高龄产妇中PGT-A提高活产率(RR 1.34,95%CI 1.02-1.77,I²=50%)。
- 非高龄产妇中PGT-A未提高活产率(RR 0.94,95%CI 0.89-0.99,I²=0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To review the effect of comprehensive chromosome screening-based preimplantation genetic testing for aneuploidy (PGT-A) in women undergoing in vitro fertilization (IVF) treatment, we conducted this meta-analysis to compare pregnancy outcomes of women who did and did not undergo such testing. DATA SOURCES: We searched Medline, EMBASE, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from their inception until February 28, 2022, for randomized controlled trials focusing on PGT-A treatment without any language restrictions. METHODS OF STUDY SELECTION: Randomized controlled trials involving women undergoing IVF with or without PGT-A and comprehensive chromosome testing. Pooled relative risks (RRs) with 95% CIs were calculated for the primary outcome using a random-effects model with the Mantel-Haenszel method. RESULTS: A total of nine trials with 3,334 participants were included. Overall, PGT-A was not associated with an increased live-birth rate (RR 1.13, 95% CI 0.96-1.34, I 2 =79%). However, PGT-A raised the live-birth rate in women of advanced maternal age (RR 1.34, 95% CI 1.02-1.77, I 2 =50%) but not in women of nonadvanced age (RR 0.94, 95% CI 0.89-0.99, I 2 =0%). CONCLUSION: Preimplantation genetic testing for aneuploidy increases the live-birth rate in women of advanced maternal age. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42022311540.
引用
- Cheng X, Zhang Y, Deng H, et al. Preimplantation Genetic Testing for Aneuploidy With Comprehensive Chromosome Screening in Patients Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis. Obstet Gynecol. 2022. PMID: 36201787. doi:10.1097/AOG.0000000000004962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。